Search

everythinglearnresearchcommunity

for

Search:↓

A 25 year old male who has been using finasteride and dutasteride for two years to treat his hair loss, with no success. Other treatments such as oral minoxidil, topical anti-androgens, RU58841, latanoprost, topical estrogen, CB 03 01, microneedling, keto 2% shampoo, vitamin D, Omega 3, B vitamins and probiotics were discussed.

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.

The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

A user is trying to reverse male pattern baldness (MPB) naturally by taking high doses of Vitamin D, improving diet, exercising, reducing stress, and other lifestyle changes, but plans to use finasteride if no results are seen in 60 days. Other users are skeptical, advising medical treatments like finasteride and warning against potential vitamin D overdose and the ineffectiveness of natural remedies for genetic hair loss.

A user found that antihistamines stop their hair loss and related symptoms, but they experience side effects like sedation and chest pain. They are seeking alternative solutions or topical antihistamines to avoid systemic side effects.

The conversation is about a 23-year-old man's positive experience with hair regrowth using oral finasteride (1mg daily) and topical minoxidil (twice daily), with initial side effects including zero libido and watery semen that resolved except for the semen consistency. He also used dermarolling initially but stopped due to brittleness.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

Topical melatonin, caffeine, and adenosine have shown impressive results in increasing hair density by 55% in 8 weeks, according to a Medium article.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A user shared their positive 3-month experience using finasteride, minoxidil, and vitamin D to treat hair loss, noting significant regrowth and minimal shedding. They also discussed potential side effects and the low likelihood of experiencing them, while being open to answering further questions.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Dutasteride at 2.5mg is considered a potential hair loss cure due to its DHT-blocking ability, but there are concerns about side effects and individual responses. Minoxidil, finasteride, and RU58841 are also discussed, with mixed opinions on their effectiveness and safety.

Finasteride and minoxidil can revive hair dormant for up to 7 years, with microneedling enhancing regrowth. Users report significant hair regrowth even after long periods of baldness.

The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.

User maintained hair with finasteride for 6 months, then switched to dutasteride for 7 months, using DHT blocking shampoo, keto 2% shampoo, and microneedling. Significant hair growth observed, especially on right temple.

User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.

Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.

Stopping saw palmetto and rosemary oil led to significant hair loss for a long-term finasteride user. Resuming saw palmetto caused side effects, and there is debate about its effectiveness and the potential impact of oxycodone on hair loss.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

Users discuss their positive experiences with finasteride for hair loss, mentioning halted hair loss, hair regrowth, and improved self-esteem. Some express satisfaction in taking action against baldness, while others note increased libido and energy.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Quitting vaping significantly reduced hair loss for a user who was a heavy vaper and also taking finasteride. Some participants suggest nicotine's vasoconstrictive properties may worsen hair loss, while others share personal anecdotes of hair improvement after quitting smoking or vaping.

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.